MedTrace Logo

Phase 1 Study of 68Ga-R8760

NCT05999292 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2024-12-09

No results posted yet for this study

Summary

A Phase 1 Safety and Dosimetry Study of 68Ga-R8760 in Patients with Adrenocortical Carcinoma and Healthy Volunteers

Conditions

  • Adrenocortical Carcinoma

Interventions

DRUG

68Ga-R8760 injection at pre-defined dose levels

PET/CT imaging at predefined timepoints

DRUG

68Ga-R8760 injection

PET/CT imaging at a single timepoint

Sponsors & Collaborators

  • Radionetics Oncology

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-11
Primary Completion
2024-05-23
Completion
2024-05-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05999292 on ClinicalTrials.gov